A multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of a subcutaneous allergoid preparation of house dust mite allergens (Dermatophagoides pteronyssinus / Dermatophagoides farinae) in patients with moderate to severe allergic rhinitis/rhinoconjunctivitis with or without controlled allergic asthma.
Not yet recruitingCTIS2026-526213-28-00
Allergopharma GmbH & Co. KGHouse dust mite allergy
Target: 492Updated: 2026-09-30